1. Zieman M, Guillebaud J, Weisberg E et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77 (Suppl. 2): 813–8.
2. Archer D, Bigrigg A, Smallwood G et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American Women. Fertil Steril 2002; 77 (Suppl. 2): S27–31.
3. Smallwood G, Meador M, Lenihan JrJ et al. For the ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gyneco 2001; 98: 799–805.
4. Audet M-C, Moreau M, Koltun W et al. For the ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA 2001; 285: 2347–54.
5. Archer D, Bigrigg A, Smallwood G et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American Women. Fertil Steril 2002; 77(Suppl. 2): S27–31.
6. Smallwood G, Meador M, Leruhan JrJ et al. For the ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gyneco 2001; 98: 799–805.
7. Audet M-C, Moreau M, Koltun W et al. For the ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA 2001; 285: 2347–54.
7. Abrams L, Skee D, Natarajan J et al. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinylestradiol at four application sites. Br J Clin Pharmacol 2002b; 53: 141–6.
8. Rosenberg M, Waugh M. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999; 180: S276–9.